Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 14/20 | 0.55 |
| ▸ | HCAR3 | P49019 | 2/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.39 |
| ▸ | IKBKB | O14920 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3452667 | 1.00 | FYN (0.55) | FYNHCAR3MKNK1IKBKB | |
| SCHEMBL13110808 | 0.86 | FYN (0.70) | FYNMKNK1 | |
| Fumaric Acid SCHEMBL3452560 | 0.86 | FYN (0.61) | FYNMKNK1IKBKB | |
| SCHEMBL13110964 | 0.85 | FYN (0.69) | FYNMKNK1 | |
| SCHEMBL13110981 | 0.85 | FYN (0.68) | FYNMKNK1 | |
| Hydrochloric Acid SCHEMBL3453207 | 0.85 | FYN (0.67) | FYNMKNK1 | |
| Hydrochloric Acid SCHEMBL3451721 | 0.84 | FYN (0.67) | FYNMKNK1 | |
| Hydrochloric Acid SCHEMBL3451716 | 0.84 | FYN (0.67) | FYNMKNK1 | |
| SCHEMBL3454664 | 0.84 | FYN (0.57) | FYNMKNK1 | |
| Fumaric Acid SCHEMBL3454184 | 0.83 | FYN (0.52) | FYNHCAR3MKNK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820670-B2 | 6-aminoimidazo[1,2-b]pyridazine analogs as rho kinase inhibitors for the treatment of rho kinase-mediated diseases and conditions | ALCON RESEARCH, LTD. (US) | 2010-10-26 | — | — | US | disclosed |
| WO-2008079880-A1 | 6-AMINOIMIDAZO[1,2-B]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION | ALCON RESEARCH, LTD. (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ALCON MANUFACTURING, LTD. (US) | 2008-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153813-A1 | 6-AMINOIMIDAZO[1,2-b]PYRIDAZINE ANALOGS AS RHO KINASE INHIBITORS FOR THE TREATMENT OF RHO KINASE-MEDIATED DISEASES AND CONDITIONS | ROCK2, ROCK1, RHOT2 | FYN 856/4885HCAR3 2276/4885MKNK1 342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.